company background image
EFTR

eFFECTOR Therapeutics NasdaqCM:EFTR Stock Report

Last Price

US$0.48

Market Cap

US$20.2m

7D

2.7%

1Y

-91.4%

Updated

27 Jan, 2023

Data

Company Financials +

eFFECTOR Therapeutics, Inc.

NasdaqCM:EFTR Stock Report

Mkt Cap: US$20.2m

EFTR Stock Overview

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

EFTR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance1/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

eFFECTOR Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for eFFECTOR Therapeutics
Historical stock prices
Current Share PriceUS$0.48
52 Week HighUS$5.97
52 Week LowUS$0.36
Beta0
1 Month Change14.69%
3 Month Change-22.27%
1 Year Change-91.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.16%

Recent News & Updates

Recent updates

Shareholder Returns

EFTRUS BiotechsUS Market
7D2.7%0.7%2.3%
1Y-91.4%7.1%-9.7%

Return vs Industry: EFTR underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: EFTR underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is EFTR's price volatile compared to industry and market?
EFTR volatility
EFTR Average Weekly Movement19.3%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: EFTR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: EFTR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201212Steve Worlandhttps://effector.com

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors.

eFFECTOR Therapeutics, Inc. Fundamentals Summary

How do eFFECTOR Therapeutics's earnings and revenue compare to its market cap?
EFTR fundamental statistics
Market CapUS$20.18m
Earnings (TTM)US$5.64m
Revenue (TTM)US$3.19m

3.6x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EFTR income statement (TTM)
RevenueUS$3.19m
Cost of RevenueUS$23.06m
Gross Profit-US$19.87m
Other Expenses-US$25.51m
EarningsUS$5.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin-623.02%
Net Profit Margin176.98%
Debt/Equity Ratio173.7%

How did EFTR perform over the long term?

See historical performance and comparison